64 results
Page 2 of 4
424B5
ksgsxs
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-1.1
m90dlh7
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
424B5
bvje4wilbqmbn iwl8
16 Jul 21
Prospectus supplement for primary offering
4:07pm
8-K
EX-10.1
1p23xl m80
13 Nov 20
Termination of a Material Definitive Agreement
4:02pm
8-K
EX-1.1
cnrx anw7
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
424B5
4k1p 8ykrfn
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
cett5 ksqtx
23 Jun 20
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
mx9xzy97gd
6 Jan 20
Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
5:01pm
8-K
EX-1.1
qifdp
25 Oct 19
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
4:03pm
424B5
ueyv0y1m8hd
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
7z3zgm81h6 5lvyu8r
22 Oct 19
Prospectus supplement for primary offering
4:24pm
S-3
0mvvhicfo06vpsg
11 Jun 19
Shelf registration
5:05pm
424B3
x29mwi mvu
12 Apr 19
Prospectus supplement
4:41pm